Clinical trials: Haematological Cancer, open to volunteers
Cancer, Chronic Lymphocytic Leukemia
Time Restricted Eating in Haematological Malignancies
The goal of this clinical trial is to learn if time restricted eating (TRE), a form of intermittent fasting, can impact health outcomes in patients with chronic lymphocytic leukemia (CLL).
- Trial name
- NCT06862323
- Testing
- Time-Restricted Eating
- Where
- Canada
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- British Columbia Cancer Agency
Haematological Malignancy, Malignant Neoplasm
DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.
This clinical trial is looking at two drugs called dabrafenib and trametinib. Dabrafenib and trametinib are approved as standard of care treatment for adult patients with melanoma (a type of skin cancer) or lung cancer and in…
- Conditions
- Haematological Malignancy, Malignant Neoplasm, Lymphoproliferative Disorders, Neoplasms by Histologic Type
- Trial name
- DETERMINE (NCT07440290)
- Testing
- Dabrafenib, Trametinib
- Where
- 27 sites in United Kingdom
- Volunteers
- 30 people
- Sponsor
- Cancer Research UK
Glioma
Investigating Mechanistic Predictors of Interpatient Variability and Temozolomide (TMZ) Induced Haematological Toxicity for Glioma Patients
A medication called temozolomide has been used for many years in the treatment of high-grade gliomas, which are tumours that originate in the brain.
- Trial name
- Improve TMZ (NCT06546631)
- Where
- Ireland
- Volunteers
- 55 people
- Sponsor
- University College Cork
Myeloma, Non-Hodgkin's Lymphoma
Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial (RATIONAL-PT)
This is an adaptive platform study to find out how safe and effective different strategies are in comparison to each other, for preventing infection in patients with blood cancers.
- Conditions
- Myeloma, Non-Hodgkin's Lymphoma, Leukemia
- Trial name
- NCT07202052
- Testing
- Intravenous immunoglobulin, Trimethoprim / Sulfamethoxazole, Amoxicillin clavulanic acid
- Where
- 3 sites in Australia
- Volunteers
- 900 people
- Sponsor
- Monash University
Thrombocytopaenia, Haematological Malignancies
Clinical Efficacy of Platelet Transfusion
The aim of this study is to analyze the effect of the storage time of platelet concentrates on the occurrence of bleeding events during prophylactic platelet transfusions in patients with hematological malignancies.
- Trial name
- ECLAT (NCT06805097)
- Testing
- Self-assessment of bleeding events
- Where
- France
- Volunteers
- 343 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Fertility Preservation, Cancer Remission
Long-term Evaluation of Fertility Preservation Options in Women in Cancer Remission or Haematological Pathology
Cancer treatments, despite their increasing effectiveness, carry a significant risk of gamete toxicity. Women of reproductive age are commonly offered fertility preservation (FP) before starting their treatment.
- Conditions
- Fertility Preservation, Cancer Remission, Reproductive Outcomes, Reproductive Health
- Trial name
- FERT-ISSUES (NCT07312058)
- Where
- France
- Volunteers
- 102 people
- Sponsor
- Centre Hospitalier Universitaire, Amiens
Haematological Malignancy, Hypogammaglobulinemia
Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Immunoglobulin Stopping or Extension
The aim of the study is to find out if patients with blood cancers receiving immunoglobulin (Ig) for the purpose of preventing infections can safety stop immunoglobulin after six months of therapy, and take oral antibiotics…
- Trial name
- RATIONALISE (NCT05678621)
- Testing
- trimethoprim-sulfamethoxazole (co-trimoxazole), amoxycillin/clavulanic acid and ciprofloxacin, Immunoglobulins
- Where
- 7 sites in Australia
- Volunteers
- 300 people
- Sponsor
- Monash University
Haematological Malignancy
Impact of Adapted Physical Activity on Patient's Recovery Following Allogeneic Stem Cell Transplantation for Hematological Malignancy
It is a study about adaptated physical activity for patients receiving a stem cell transplantation. They will benefit of 6 adaptated individuals lessons at home between 1 month and 3 months after stem cell transplantation.
- Trial name
- APALLO (NCT05379738)
- Testing
- 6 sessions of adapted physical activity after stem cell transplant
- Where
- France
- Volunteers
- 75 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Haematological Malignancy
Safety and Feasibility of a Multidisciplinary Programme of Integrated Hospital-home Management With Early Discharge of Patients With Haematological Malignancies Undergoing High-dose Chemotherapy in Hospital
Patients undergoing particular intensive and (sub)myeloablative chemotherapy regimens with subsequent autologous stem cell transplant currently have a relatively low rate of therapy-related complications, both infectious and…
- Trial name
- AMICO (NCT06814405)
- Testing
- Home patient management, Hospital patient management
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Fungal Infection, Haematological Malignancy
Pharmacogenomics for Better Treatment of Fungal Infections Clinical Trial
This project aims to address invasive fungal infections in patients, by precision dosing of voriconazole based on CYP2C19 genotype testing with Bayesian dose-forecasting dosing software to develop patient-centric and maximally…
- Conditions
- Fungal Infection, Haematological Malignancy, Blood Cancer, Infectious Disease
- Trial name
- PRAGMATIC (NCT06510699)
- Testing
- genotype-directed dosing with dosing software based on therapeutic drug monitoring
- Where
- 7 sites in United States, Australia
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- The University of Queensland
Extrahepatic Portal Vein Obstruction (EHPVO), Thrombophilia
Hematological Disorders in EHPVO Patients
This study focuses on patients who have a condition called extrahepatic portal vein obstruction (EHPVO), where a blood clot blocks the portal vein outside the liver.
- Conditions
- Extrahepatic Portal Vein Obstruction (EHPVO), Thrombophilia, Myeloproliferative Neoplasms (MPN), Antiphospholipid Syndrome (APS)
- Trial name
- EHPVO-HEM (NCT07108023)
- Testing
- No intervention (Observational Study)
- Volunteers
- 115 people
- Sponsor
- Rahab Nady
Hematologic Cancer, CRS - Cytokine Release Syndrome
Early Detection of Complications During Immunotherapy for Haematological Malignancy
Aims To identify patients that should remain admitted in hospital for more intense surveillance because of high risk for development of clinical complications Expand the understanding of the interactions between physiology and…
- Trial name
- NCT06377059
- Testing
- WARD
- Where
- Denmark
- Volunteers
- 100 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Haematological Malignancy, Melanoma
DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.
This clinical trial is looking at a combination of drugs called vemurafenib and cobimetinib. Vemurafenib is approved as standard of care for adult patients with unresectable or metastatic melanoma.
- Conditions
- Haematological Malignancy, Melanoma, Thyroid Cancer, Papillary, Ovarian Neoplasms
- Trial name
- DETERMINE (NCT05768178)
- Testing
- Vemurafenib, Cobimetinib
- Where
- 16 sites in United Kingdom
- Volunteers
- 30 people
- Sponsor
- Cancer Research UK
Waldenstrom Macroglobulinaemia, Multiple Myeloma
BLOOD-dose: A Platform Trial Evaluating Dose Optimization in Hematological Diseases.
BLOOD-dose is a multicentre, adaptive, randomized, multidomain platform trial designed to optimize treatment dosing strategies in adult patients with haematological diseases.
- Trial name
- BLOOD-dose (NCT07474961)
- Testing
- teclistamab OR talquetamab OR elranatamab OR linvoseltamab, BTK inhibitors (ibrutinib and zanubrutinib)
- Where
- 5 sites in Denmark
- Volunteers
- 400 people
- Sponsor
- Anne Louise Tølbøll Sørensen
Solid Tumour, Haematological Malignancy
DETERMINE Trial Treatment Arm 06: Capmatinib in Adult Patients With Cancers Harbouring MET Dysregulations
This clinical trial is looking at a drug called capmatinib. Capmatinib is approved as standard of care treatment for adult patients with certain types of lung cancer.
- Conditions
- Solid Tumour, Haematological Malignancy, Malignant Neoplasm, Neoplasms by Histologic Type
- Trial name
- DETERMINE (NCT06988475)
- Testing
- Capmatinib
- Where
- 17 sites in United Kingdom
- Volunteers
- 30 people
- Sponsor
- Cancer Research UK
Haematological Malignancy, Malignant Neoplasm
DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Cancers
This clinical trial is looking at a drug called alectinib. Alectinib is approved as standard of care treatment for adult patients with certain types of lung cancer.
- Conditions
- Haematological Malignancy, Malignant Neoplasm, Lymphoproliferative Disorders, Neoplasms by Histologic Type
- Trial name
- DETERMINE (NCT05770037)
- Testing
- Alectinib
- Where
- 27 sites in United Kingdom
- Volunteers
- 30 people
- Sponsor
- Cancer Research UK
Haematological Malignancy, Solid Tumour
DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol
DETERMINE is an open-label phase II/III trial. It will look at targeted treatments in rare cancers or common cancers with rare genetic change (mutation). Patients must have a cancer with an identified mutation.
- Trial name
- DETERMINE (NCT05722886)
- Testing
- Alectinib, Atezolizumab, Entrectinib
- Where
- 27 sites in United Kingdom
- Volunteers
- 825 people
- Sponsor
- Cancer Research UK
Large B-Cell Lymphoma (LBCL), Multiple Myeloma (MM)
Restrictive Versus Standard Antibiotic Treatment During CAR-T Therapy
The purpose of the CARMic study is to investigate whether a restrictive, microbiome-sparing antibiotic strategy can better preserve the gut microbiota in patients undergoing chimeric antigen receptor T-cell (CAR-T) therapy…
- Conditions
- Large B-Cell Lymphoma (LBCL), Multiple Myeloma (MM), Gut Microbiota
- Trial name
- CARMic (NCT07842198)
- Testing
- ceftazidime, ciprofloxacin, Standard-of-Care Antibiotic Strategy
- Where
- Denmark
- Volunteers
- 150 people
- Sponsor
- Zealand University Hospital
Cancer, Malignancy
Allogeneic NKG2DL-targeting CAR γδ T Cells (CTM-N2D) in Advanced Cancers (ANGELICA)
CAR-T is a pioneering cancer treatment which has found success in some cancers. This treatment is made first by taking blood cells from the patient.
- Conditions
- Cancer, Malignancy, Refractory Cancer, Relapsed Cancer
- Trial name
- ANGELICA (NCT05302037)
- Testing
- Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T Cells (CTM-N2D)
- Where
- Singapore
- Volunteers
- 12 people
- Sponsor
- CytoMed Therapeutics Pte Ltd
Haematological Cancer, Healthy
Pulsed Electromagnetic Fields in Preventing Physical Deconditioning in Patients Undergoing Prolonged Hospitalization
The goal of this clinical trial is to examine if pulsed electromagnetic fields (PEMF) can prevent or decrease physical deconditioning associated with prolonged hospitalisation and immobility of haematology patients.
- Trial name
- PEMF (NCT06744764)
- Testing
- PEMF (1mT), PEMF (0mT)
- Where
- 2 sites in Singapore
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- National University Hospital, Singapore